Related Experiment Video
Updated: Aug 7, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Clotting factor concentrates and immune function in haemophilic patients
1Department of Pediatrics and Internal Medicine, Gulf State Hemophilia Center, Houston, TX 77030, USA.
Summary
Patients with hemophilia experience immune dysfunction due to clotting factor concentrates (CFCs). Very high-purity CFCs appear to preserve immune function better than intermediate-purity ones, potentially reducing infection risks.
Area of Science:
- Immunology
- Hematology
- Virology
Background:
- Patients with hemophilia often have immune system disturbances.
- While viral infections contribute, chronic exposure to proteins in clotting factor concentrates (CFCs) may also impair immune function.
- Protein contaminants in CFCs, like immunoglobulins, can suppress immune indicators.
Purpose of the Study:
- To investigate the impact of different purity levels of CFCs on immune function in hemophilia patients.
- To compare the effects of intermediate-purity versus very high-purity CFCs on immune markers, particularly CD4+ lymphocyte counts.
- To assess the potential benefits of very high-purity CFCs in preserving immune function and reducing infection risk.
Main Methods:
- Review of in vitro and ex vivo studies examining immune function indicators.
- Analysis of studies comparing immune responses to intermediate-purity and very high-purity CFCs.
- Correlation analysis between CFC administration and immune suppression, including CD4+ lymphocyte counts.
Main Results:
- Intermediate-purity CFCs generally show more immune inhibition than very high-purity CFCs.
- Immunosuppression often correlates with the cumulative dose of intermediate-purity CFCs.
- Very high-purity CFCs are associated with better preservation of CD4+ lymphocytes compared to intermediate-purity ones.
Conclusions:
- Current evidence suggests very high-purity CFCs are preferable for hemophilia patients.
- Very high-purity CFCs may help preserve immune function and reduce the risk of viral infections like hepatitis.
- Further research is needed to confirm long-term clinical benefits of very high-purity CFCs.
More Related Videos
09:38A Microfluidic Flow Chamber Model for Platelet Transfusion and Hemostasis Measures Platelet Deposition and Fibrin Formation in Real-time
Published on: February 14, 2017
08:01The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
Related Concept Videos
01:01Regulation of Hematopoietic Stem Cells
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.